Please contact us for more information or to learn if you are eligible to participate.
The primary objective of this study is to compare the progression-free survival (PFS) between control treatment and experimental treatment strategies: ibrutinib/obinutuzumab (IO) with ibrutinib maintenance (IM) versus ibrutinib/venetoclax/obinutuzumab (IVO) regardless of IM or observation.
Jose Cruz, MD
National Cancer Institute (NCI)
Type of Trial